Considering the relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how will hybrid capture-based whole exome NGS guide precision-based treatment?

Considering the relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how will hybrid capture-based whole exome NGS guide precision-based treatment?

In light of increasing evidence suggesting a relationship between total mutational burden and responsiveness to immune checkpoint inhibition, how are you positioning the role of hybrid capture-based whole exome NGS to guide precision-based cancer treatment?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Rodrigo Dienstmann, MD

Rodrigo Dienstmann, MD

Principal Investigator, Oncology Data Science (ODysSey) Group
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Computational Oncology Group
Sage Bionetworks
Seattle, Washington, USA